Rate My Professor Jyoti Choudhary

Professor Jyoti S. Choudhary is Professor and Group Leader of the Functional Proteomics group at The Institute of Cancer Research (ICR), London, where she also serves as Head of the Proteomics Core Facility and Career Faculty Leader. She earned her BSc (Hons) in Biochemistry and PhD in Biochemistry from Imperial College London, with her doctoral research in biological mass spectrometry under Professor Howard Morris FRS. Her professional career commenced as a senior scientist in the Bioanalytical Sciences division at GlaxoWellcome, where she led the CellMap project on proteomics technologies for drug discovery. This initiative spun out to GlaxoSmithKline and Cellzome AG, where she was a founding member advancing interaction and chemical proteomics for target identification and drug development. In 2004, she joined the Wellcome Trust Sanger Institute, pioneering interaction proteomics and proteogenomics, including endogenous gene tagging, eTAP in mouse stem cells, and open-access computational tools to integrate proteomics with genomics for genome annotation and genetic variation studies. Since moving to ICR in 2017, she leads efforts applying quantitative proteomics and proteogenomics to cancer research. She holds visiting scientist positions at Imperial College London and the Wellcome Trust Sanger Institute and is a member of the Cancer Research UK Convergence Science Centre.

Choudhary's research centers on understanding how protein network organization and dynamics drive cancer progression and resistance, particularly the impact of mutations and genetic variation on proteome attributes using quantitative mass spectrometry. Her group develops novel experimental and computational proteomics techniques to profile protein interactions, signaling, post-translational modifications, and expression in cancer. Key contributions include proteomic landscapes of breast cancer drivers, AI-analyzed bacterial effector networks, and mutation effects on bowel cancer protein networks. Major publications encompass 'LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma' (Cancer Research, 2026), 'Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansion' (Cell Reports, 2026), 'Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors' (Nature Communications, 2026), and 'UltraPlex-TMT: Expanding Isobaric Hyperplexing via Orthogonal Protease Cleavage' (Journal of Proteome Research, 2026).